- PLATFORM LOGINS
- |
- CONTACT
- Request a Demo
-
Collaboration will provide access to data around real-time outcomes including clinical trial matches and cost analysis to the network of community cancer centers treating patients with rare and common cancers
The two
TransMed’s Clinical Practice Suite will provide oncology practices with applications that identify treatment options and historical outcomes for a group of similar patients, including a precision medicine report. Each patient population report will include patient count, mean survival time, death rate, and any complication associated with a particular treatment. This is made possible through TransMed’s Precision Medicine Platform, a patented data science which has been supporting other major consortiums around the world.
“We are thrilled to join forces with TransMed to provide community
oncologists with access to data to support their efforts and understand
the underlying mechanisms of cancer,” stated
“At TransMed Systems, we are constantly working to develop and deliver
software tools that facilitate the analysis and application of
translational data,” stated
“Through this partnership, we are ensuring that patients at community
oncology centers have access to quality clinical trials right in their
own backyard,” stated
Cautionary Note Concerning Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including, among
others, statements regarding the capabilities and anticipated utility of
our GPS Cancer, including predicting patient response and resistance to
therapeutics, enabling diagnoses by physicians and accelerating efforts
to bring novel combinations of therapeutic agents to cancer patients, as
well as our contribution to the Cancer 2020 initiative. Forward-looking
statements are subject to numerous risks and uncertainties that could
cause actual results to differ materially from currently anticipated
results. Factors that may cause future results to differ materially from
management’s current expectations include, among other things, that GPS
Cancer may not perform as anticipated, that sufficient physicians may
not adopt GPS Cancer to assist their diagnoses or that healthcare payers
may not provide reimbursement for GPS Cancer as expected. Our business
is subject to numerous additional risks and uncertainties, including,
among others, risks relating to market acceptance of our products; our
ability to successfully launch new products and applications;
competition; our sales, marketing and distribution capabilities; our
planned sales, marketing, and research and development activities;
unanticipated increases in costs or expenses; and risks associated with
international operations. Information on these and additional risks,
uncertainties, and other information affecting our business and
operating results can be found in our existing and future filings with
the
About NantCare
NantCare, a member of the
About GPS Cancer™
GPS Cancer™ is a comprehensive molecular
profile available through
About
About TransMed Systems
TransMed Systems develops and deploys
software solutions that facilitate exploration, reporting, and analysis
of clinical, molecular, and healthcare operational data. TransMed’s BIS
provides an integrated bio-informatics platform enabling clinical and
research organizations to aggregate data from multiple sources, easily
explore data, and perform research and/or practice specific analysis.
TransMed’s platform unlocks the potential of the healthcare repository
by tightly integrating analytics with aggregated data providing
selfservice analysis of all bio-clinical data sources in a framework
usable by clinicians and investigators. Our solutions are used by health
sciences researchers as well as clinicians interested in the application
of information technology to the challenges of basic research and
turning research into improved clinical practices. Our
View source version on businesswire.com: http://www.businesswire.com/news/home/20161207005633/en/
jhodson@nantworks.com
Source: